Pathalys Pharma is a late-stage clinical biopharmaceutical company based in Research Triangle Park, NC, focused on therapies for end-stage kidney disease (ESKD). Its initial asset is upacicalcet, a novel calcimimetic intended to improve treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is running two ongoing clinical trials of upacicalcet and intends to use new financing to finalize those studies. Pathalys plans to execute an NDA filing with the U.S. Food and Drug Administration and accelerate preapproval commercialization preparations. Beyond upacicalcet, the company continues to identify additional needs and potential therapeutic solutions for patients with ESKD. The recent financing is intended to support late-stage development, regulatory submission, and commercialization readiness. Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on developing advanced therapeutics for end-stage kidney disease (ESKD). Its lead asset is upacicalcet, a novel calcimimetic aimed at improving treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is led by CEO Neal Fowler and continues to identify other high-priority needs and potential solutions for patients with ESKD. Pathalys has entered a collaboration with Launch Therapeutics to advance the phase 3 clinical trials for upacicalcet; Launch Therapeutics is backed by funds managed by Carlyle and Abingworth. The recently announced financing will support two phase 3 trials, regulatory registration efforts, and pre-commercialization activities for upacicalcet. Pathalys remains a privately held, late-stage clinical-stage biopharma working toward commercialization of its initial asset.

Total raised

$255M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2024